A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
NCT ID: NCT00179738
Last Updated: 2005-11-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
40 participants
INTERVENTIONAL
2005-04-30
2007-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CC5013
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age \> or = to 18 years at the time of signing the informed consent form.
3. Able to adhere to the study visit schedule and other protocol requirements.
4. Must have a histologic diagnosis of adenocarcinoma of the prostate.
5. Must be surgically or medically castrated. If the method is medical castration, the subject must have a serum testosterone level of \<50 ng/dl. The subject should maintain treatment with LH RH antagonists or agonists.
6. Must have prostate cancer unresponsive or refractory to androgen blockade as demonstrated by rising PSA.
-Rising PSA is defined as at least 2 consecutive rises in PSA to be documented over the reference value (measure 1). The first rising PSA (measure 2) must be taken at least 7 days after the reference value.
A third confirmatory PSA is required, and it must be obtained at least seven days after the second measure. If this is not greater than measure 2, a fourth PSA is required and this must be greater than measure 2.
-Absolute value of PSA \> or = to 5 ng/ml on the last confirmatory assessment.
7. Prior treatment with antiandrogens such as flutamide, or other hormonal agents such as estrogens, corticosteroids, or ketoconazole must have been stopped for at least 28 days prior to treatment.
In the case of nilandron and bicalutamide, treatment with these agents must have stopped at least 42 days prior to treatment. Following completion of the antiandrogen withdrawal period, either:
* One post withdrawal PSA value must be higher than the last pre-withdrawal PSA value, or
* If the subject's PSA value decreased following the antiandrogen withdrawal period then two increases in PSA values must be documented after the post-withdrawal nadir.
8. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (Appendix II: ECOG Performance Status Scale).
Exclusion Criteria
2. Any of the following laboratory abnormalities:
1. Absolute neutrophil count (ANC) \<1,500 cells/mm3 (1.5 x 109/L)
2. Platelet count \<100,000 cells/mm3 (100 x 109/L)
3. Serum creatinine \>2.5 mg/dL (221 mmol/L)
4. Serum SGOT/AST or SGPT/ALT \>3.0 x upper limit of normal (ULN)
5. Serum total bilirubin \>2.0 mg/dL (34 mmol/L)
3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study or confounds the ability to interpret data from the study.
4. Prior history of malignancies other than AIPC (except for basal cell or squamous cell carcinoma of the skin) unless the subject has been free of the disease for \> or = to 1 year.
5. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
6. Prior \> or = to grade 3 allergic reaction/hypersensitivity to thalidomide.
7. Prior \> or = to grade 3 rash or any desquamating (blistering) rash while taking thalidomide.
8. Prior use of lenalidomide.
9. Prior use of chemotherapy for androgen independent prostate cancer.
10. Use of any standard/experimental anti-cancer drug therapy within 28 days of the initiation of study drug therapy except LHRH agonists/antagonists.
11. Known active Hepatitis C.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prologue Research International
INDUSTRY
Celgene Corporation
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alta Bates Cancer Center
Berkeley, California, United States
Moffit Cancer Center
Tampa, Florida, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CC-5013-PC-001
Identifier Type: -
Identifier Source: org_study_id